BOLDpharma is an initiative launched earlier this year by digital agency Anthill, together with key industry figures, to address the lack of confidence the industry has sometimes shown, and which makes it hard to launch "big ideas that create real change". The initiative is designed "to be the thought provocation that our industry needs, and to inspire and build a community of like-minded individuals to encourage innovation in pharma – confident, challenging, bold-thinking people who will drive the industry’s development in the years to come", says the agency.
One of the initial calls to action is the BOLD Survey, which has just been launched to uncover precisely what is holding people back. Initial results highlight the great potential for the industry to work in new ways – but there needs to be action. 89% of respondents believed that their organization is not fully-utilizing the technology at their disposal and less than 20% believed that an innovative initiative would be supported within their organization.
"This movement has the potential to drastically improve the state of healthcare. There’s strength in numbers and the BOLD movement has already begun highlighting that the numbers are on the side of pro-active change," says Anthill.
To be part of the BOLDpharma initiative, follow this link to take part in the survey and receive a personal profile in relation to some key BOLD metrics. Further information can be found on Twitter, @BOLDpharma and the BOLDPharma website.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.